Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management

  • Hilman Zulkifli Amin Mail School of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Lukman Zulkifli Amin Department of Internal Medicine, School of Medicine, Universitas Indonesia, Jakarta, Indonesia.
  • Firman Zulkifli Amin School of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Keywords:
No Kewords##

Abstract

No Abstract

References

Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93(9):1137-46.

Amin HZ, Mori S, Sasaki N, Hirata K. Diagnostic approach to cardiac amyloidosis. Kobe J Med Sci. 2014; 60(1):E5-11.

Macdonald PS. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Clinical Therapeutics. 2015; 37(10):2199-205.

Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36:1990-7.

Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC: Heart Failure. 2014; 2(6):663-70.

Richards AM. Angiotensin 2 type 1 receptor blockade with neprilysin inhibition for chronic heart failure: a new paradigm. Ann Acad Med Singapore. 2015; 44(8):272-3.

McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999; 8:79-84.

Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004; 17:103-11.

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS Randomised Trial. Lancet. 2000; 356(9243):1774.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131:54-61.

Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet. 2012; 380:1387-95.

Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin-II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study. Lancet. 2010; 375:1255-66.

Published
2017-01-14
How to Cite
1.
Zulkifli Amin H, Zulkifli Amin L, Zulkifli Amin F. Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management. Acta Med Iran. 54(12):823-824.
QRcode
Section
Letter to the Editor